IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer
Baird, Anne-Marie, Leonard, Jennifer, Naicker, Krishna M., Kilmartin, Lisa, O'Byrne, Kenneth J., & Gray, Steven G. (2013) IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer. Lung Cancer, 79(1), pp. 83-90.
IL-23 is a member of the IL-6 super-family and plays key roles in cancer. Very little is currently known about the role of IL-23 in non-small cell lung cancer (NSCLC).
RT-PCR and chromatin immunopreciptiation (ChIP) were used to examine the levels, epigenetic regulation and effects of various drugs (DNA methyltransferase inhibitors, Histone Deacetylase inhibitors and Gemcitabine) on IL-23 expression in NSCLC cells and macrophages. The effects of recombinant IL-23 protein on cellular proliferation were examined by MTT assay. Statistical analysis consisted of Student's t-test or one way analysis of variance (ANOVA) where groups in the experiment were three or more.
In a cohort of primary non-small cell lung cancer (NSCLC) tumours, IL-23A expression was significantly elevated in patient tumour samples (p<0.05). IL-23A expression is epigenetically regulated through histone post-translational modifications and DNA CpG methylation. Gemcitabine, a chemotherapy drug indicated for first-line treatment of NSCLC also induced IL-23A expression. Recombinant IL-23 significantly increased cellular proliferation in NSCLC cell lines.
These results may therefore have important implications for treating NSCLC patients with either epigenetic targeted therapies or Gemcitabine. © 2012 Elsevier Ireland Ltd.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Keywords:||Epigenetics, Gemcitabine, IL-23, Non-small cell lung cancer, DNA methyltransferase inhibitor, histone deacetylase inhibitor, interleukin 23, interleukin 23p19, article, assay, cell proliferation, chromatin immunoprecipitation, cohort analysis, controlled study, DNA methylation, histone modification, human, human cell, large cell carcinoma, lung adenocarcinoma, lung non small cell cancer, lung squamous cell carcinoma, macrophage, priority journal, protein expression, protein processing, reverse transcription polymerase chain reaction, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cohort Studies, Deoxycytidine, DNA Modification Methylases, Epigenesis, Genetic, Gene Expression Regulation, Histone Deacetylase Inhibitors, Humans, Interleukin-23, Lung Neoplasms, Macrophages, Neoplasm Staging, Tumor Cells, Cultured|
|Divisions:||Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
|Copyright Owner:||Copyright 2013 Elsevier Ireland Ltd|
|Deposited On:||26 Nov 2013 03:38|
|Last Modified:||30 Jul 2014 02:06|
Repository Staff Only: item control page